Evidence map›Paper›PMID 26115881›Full record

Trial reportThe International journal on drug policy2015

Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.

Maryam Alavi, Tim Spelman, Gail V Matthews, Paul S Haber, Carolyn Day, Ingrid van Beek, Nick Walsh, Barbara Yeung, Julie Bruneau, Kathy Petoumenos and 6 more

Open access · greenAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The International journal on drug policy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. [Antiviral treatment for hepatitis C among injecting drug users in the era of direct-acting antiviral agents].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 2 countries.

Maryam AlaviThe Kirby Institute, UNSW Australia, Sydney, Australia. Electronic address: msalehialavi@kirby.unsw.edu.au.
Tim SpelmanBurnet Institute, Melbourne, Australia.
Gail V MatthewsThe Kirby Institute, UNSW Australia, Sydney, Australia.
Paul S HaberDrug Health Services, Central Clinical School (C39), University of Sydney, Sydney, Australia; Central Clinical School, University of Sydney, Sydney, Australia.
Carolyn DayCentral Clinical School, University of Sydney, Sydney, Australia.
Ingrid van BeekKirketon Road Centre, Sydney, Australia.
Nick WalshDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Barbara YeungThe Kirby Institute, UNSW Australia, Sydney, Australia.
Julie BruneauCentre de Recherche, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Canada.
Kathy PetoumenosThe Kirby Institute, UNSW Australia, Sydney, Australia.
Kate DolanNational Drug and Alcohol Research Centre, The University of New South Wales, Sydney, Australia.
John M KaldorThe Kirby Institute, UNSW Australia, Sydney, Australia.
Gregory J DoreThe Kirby Institute, UNSW Australia, Sydney, Australia.
Margaret HellardBurnet Institute, Melbourne, Australia.
Jason GrebelyThe Kirby Institute, UNSW Australia, Sydney, Australia.
ATAHC Study Group
Burnet Institute · AUUniversity of Sydney · AUCentre Hospitalier de l’Université de Montréal · CAMonash University · AUUNSW Sydney · AU

Funding

Treatment of recently acquired hepatitis C virus infectionR01DA015999 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DORE, GREGORY JOHN · 2003 to 2014
$3.7M
NIDA NIH HHS R01 DA015999NIDA NIH HHS R01DA015999
6 · The paper itself

Abstract

backgroundA barrier to hepatitis C virus (HCV) treatment among people who inject drugs (PWID) has been a concern that interferon-based HCV treatment may increase injecting risk behaviours. This study evaluated recent (past month) injecting risk behaviours during follow-up among PWID that did and did not receive HCV treatment.

methodsThe Australian Trial in Acute Hepatitis C (ATAHC) was a prospective study of natural history and treatment of recent HCV infection. Analyses were performed using generalized estimating equations.

resultsAmong 124 participants with a history of injecting drug use (median age 32 years), 69% were male, and 68% were treated for HCV infection. HCV treatment was not associated with an increase in recent injecting drug use (adjusted odds ratio (aOR) 1.06, 95% CI 0.93, 1.21) or recent used needle and syringe borrowing during follow-up (aOR 0.99, 95% CI 0.89, 1.08). HCV treatment was associated with a decrease in recent ancillary injecting equipment sharing during follow-up (aOR 0.85, 95% CI 0.74, 0.99). Further, among treated participants who remained in follow-up (n=24), ancillary injecting equipment sharing significantly decreased from 54% at enrolment to 17% during follow-up (P=0.012).

conclusionsHCV treatment was not associated with drug use or used needle and syringe borrowing during follow-up, but was associated with decreased ancillary injecting equipment sharing during follow-up. Programs to enhance HCV assessment and treatment among PWID should be expanded, given that HCV treatment does not lead to increases in injecting risk behaviours and has previously been demonstrated to be safe and effective among PWID.

Indexed as

Risk-TakingAdultAntiviral AgentsAustraliaDrug UsersFemaleHepatitis CHumansInterferon-alphaMaleNeedle SharingOdds RatioPatient DropoutsPolyethylene GlycolsRecombinant ProteinsSubstance Abuse, IntravenousAntiviral AgentsInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsAntiviral therapyHCVInjecting drug usePeople who inject drugs

Identifiers

PMID26115881
PMCPMC4577441
OpenAlexW1801566764

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.